Abstract
Despite the large number of antifungal agents currently available, very few are effective against life-threatening mycoses. In particular, the management of aspergillosis is a therapeutic challenge because of difficulties in diagnosing the infection, and the limited number of well tolerated drugs that are active in vivo against Aspergillus species, says Professor Glyn Evans from the University of Leeds, UK. His comments were directed at delegates attending a Pfizer-sponsored symposium on its latest broad-spectrum antifungal, voriconazole * , held during the 4th Congress of the European Confederation of Medical Mycology [ Glasgow, Scotland; May 1998 ].
This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Jack, D. Voriconazole. Inpharma Wkly. 1146, 7–8 (1998). https://doi.org/10.2165/00128413-199811460-00016
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-199811460-00016